Ieq Capital LLC acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 141,937 shares of the biopharmaceutical company's stock, valued at approximately $16,201,000. Ieq Capital LLC owned about 0.06% of Insmed at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Focus Advisor Solutions LLC bought a new position in shares of Insmed during the third quarter valued at approximately $2,830,000. Rothschild Investment LLC boosted its stake in shares of Insmed by 4,724.9% during the 3rd quarter. Rothschild Investment LLC now owns 11,821 shares of the biopharmaceutical company's stock valued at $1,349,000 after purchasing an additional 11,576 shares in the last quarter. Banco Santander S.A. bought a new stake in shares of Insmed during the 3rd quarter valued at about $1,043,000. SBI Okasan Asset Management Co.Ltd. increased its position in shares of Insmed by 22.4% during the third quarter. SBI Okasan Asset Management Co.Ltd. now owns 18,000 shares of the biopharmaceutical company's stock valued at $2,081,000 after buying an additional 3,300 shares during the period. Finally, HighTower Advisors LLC increased its position in shares of Insmed by 14.6% during the third quarter. HighTower Advisors LLC now owns 4,882 shares of the biopharmaceutical company's stock valued at $557,000 after buying an additional 621 shares during the period.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on INSM shares. Jefferies Financial Group reissued a "buy" rating and issued a $175.00 target price on shares of Insmed in a research report on Thursday, August 6th. Roth Capital restated a "buy" rating and issued a $198.00 price target (down from $212.00) on shares of Insmed in a research note on Tuesday, September 15th. Mizuho set a $154.00 price objective on shares of Insmed in a research report on Thursday, October 29th. Guggenheim reduced their price objective on shares of Insmed from $205.00 to $201.00 and set a "buy" rating for the company in a research note on Monday, November 2nd. Finally, Truist Financial reiterated a "buy" rating and issued a $195.00 target price (up from $185.00) on shares of Insmed in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and a consensus target price of $196.52.
View Our Latest Stock Analysis on Insmed
Insider Activity at Insmed
In other news, Director David Brennan sold 25,000 shares of the business's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. The trade was a 38.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Orlov Nicole Schaeffer sold 101,100 shares of the company's stock in a transaction that occurred on Thursday, November 19th. The shares were sold at an average price of $145.26, for a total value of $14,685,786.00. Following the sale, the insider owned 41,895 shares in the company, valued at approximately $6,085,667.70. This trade represents a 70.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company's stock.
Key Insmed News
Here's some of the latest news about INSM:
- Positive Sentiment: Reports that Sanofi is exploring a potential acquisition drove a strong rally in Insmed shares. One analyst cited in coverage suggested a takeover could value the stock at $170–$210 per share, although no deal has been announced. Insmed shares jump as Sanofi weighs potential takeover
- Neutral Sentiment: An Insmed insider sold 101,100 shares, reducing her stake by about 71%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may temper concerns that the sale reflects a reaction to recent developments.
- Negative Sentiment: The takeover reports are speculative, and analysts are divided over whether a deal would bring pipeline benefits or create financial strain. The lack of a confirmed offer may contribute to caution and profit-taking after the previous session’s surge. Analysts split on potential Sanofi-Insmed deal
Insmed Stock Down 2.2%
Shares of INSM opened at $141.33 on Friday. The firm has a fifty day simple moving average of $111.09 and a two-hundred day simple moving average of $122.71. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75.
Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to analysts' expectations of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The business's quarterly revenue was up 268.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.75) earnings per share. On average, equities research analysts expect that Insmed, Inc. will post -1.86 EPS for the current year.
Insmed Company Profile
(
Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.